A Phase 3 interventional study of Formoterol Fumarate in COPD, sponsored by Dey. Completed at 68 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2010-11-11.
Sponsored by Dey (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 24th largest by enrollment, is one of 40 in phase 3, and was the 4th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 690 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 89 interventional studies. Of the 80 that completed or were terminated, 38 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 89 have an industry lead sponsor. The 10 most frequent:
This study is registered under Dey, one of the names counted as Viatris Inc.. Under that name alone:
Dey is the lead sponsor of 21 studies on the registry; none are open to participants now.
26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc.: none open now, none under way, none of them phase 3. Of 26 finished, 11 (42%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc., this one is the 3rd largest by enrollment, is one of 12 in phase 3, and was the 1st registered.
Viatris Inc.’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2005.
1 of the studies testing formoterol in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 26 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measure of lung function
Change in lung function, as well as vital signs
Physical Exam results, Adverse Event reporting, etc
This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Formoterol
Pulmonary Disease, Chronic Obstructive →